|
|
The future of effective aerosol therapies
lies in the optimization of drug-to-device and
device-to-drug.
PARI Pharma has taken the
next step and combined
formulation development,
next generation aerosol
platforms, and aerosol characterization under
one roof.
We are currently working on formulations
optimized to our Advanced Aerosol Delivery
platform - eFlow®.
This multifunctional development program is the
key to creating targeted therapies with high
deposition amounts, low side-effect profiles,
improved patient compliance…and happier,
healthier patients.
After 100 years, we know aerosol science
and aerosol delivery.
|
|
|
|
 |
| |
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans [more]
- - - - - - - - - - - - - - - -
PARI Pharma’s Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS [more]
- - - - - - - - - - - - - - - -
PARI Pharma Receives 2nd ODD from EMEA; Moves Inhaled Tobramycin – eFlow Technology Program Forward [more] |
|
| |
|
